Evidence map›Paper›PMID 34220829›Full record

ArticleFrontiers in immunology2021

S100a9 Protects Male Lupus-Prone NZBWF1 Mice From Disease Development.

Laura M Davison, Andres A Alberto, Hardik A Dand, Emma J Keller, Madeline Patt, Ayesha Khan, Nina Dvorina, Alexandra White, Nodoka Sakurai, Lauren N Liegl and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. S100a9 Protects Against the Effects of Repeated Social Defeat Stress.Biological psychiatry global open science · 2023
    Article
  9. The ion transporter NaScience advances · 2023
    Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Laura M DavisonCleveland Clinic Lerner College of Medicine, Department of Molecular Medicine, Case Western Reserve University, Cleveland, OH, United States.
Andres A AlbertoDepartment of Inflammation and Immunity, Lerner Research Institute, NE40, Cleveland Clinic Foundation, Cleveland, OH, United States.
Hardik A DandDepartment of Inflammation and Immunity, Lerner Research Institute, NE40, Cleveland Clinic Foundation, Cleveland, OH, United States.
Emma J KellerCleveland Clinic Lerner College of Medicine, Department of Molecular Medicine, Case Western Reserve University, Cleveland, OH, United States.
Madeline PattDepartment of Inflammation and Immunity, Lerner Research Institute, NE40, Cleveland Clinic Foundation, Cleveland, OH, United States.
Ayesha KhanDepartment of Inflammation and Immunity, Lerner Research Institute, NE40, Cleveland Clinic Foundation, Cleveland, OH, United States.
Nina DvorinaDepartment of Inflammation and Immunity, Lerner Research Institute, NE40, Cleveland Clinic Foundation, Cleveland, OH, United States.
Alexandra WhiteCleveland Clinic Lerner College of Medicine at Case Western Reserve University, Cleveland, OH, United States.
Nodoka SakuraiDepartment of Inflammation and Immunity, Lerner Research Institute, NE40, Cleveland Clinic Foundation, Cleveland, OH, United States.
Lauren N LieglDepartment of Inflammation and Immunity, Lerner Research Institute, NE40, Cleveland Clinic Foundation, Cleveland, OH, United States.
Thomas VoglInstitute of Immunology, University of Muenster, Muenster, Germany.
Trine N JorgensenDepartment of Inflammation and Immunity, Lerner Research Institute, NE40, Cleveland Clinic Foundation, Cleveland, OH, United States.
Cleveland Clinic · USCase Western Reserve University · USCleveland Clinic Lerner College of Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disorder disproportionally affecting women. A similar sex difference exists in the murine New Zealand Black/White hybrid model (NZBWF1) of SLE with all females, but only 30-40% of males, developing disease within the first year of life. Myeloid-derived suppressor cells (MDSCs) are prominent in NZBWF1 males and while depletion of these cells in males, but not females, promotes disease development, the mechanism of suppression remains unknown. S100a9, expressed by neutrophils and MDSCs, has previously been shown to exert immunosuppressive functions in cancer and inflammation. Here we investigated if S100a9 exerts immunosuppressive functions in NZBWF1 male and female mice.

Indexed as

Disease SusceptibilityAnimalsAutoantibodiesCalgranulin BDisease Models, AnimalFemaleGene ExpressionGenetic Predisposition to DiseaseGlomerulonephritisHumansImmunohistochemistryImmunophenotypingLupus Erythematosus, SystemicLymphocyte ActivationLymphocytesMaleAutoantibodiesCalgranulin BS100A9 protein, mouseautoantibodylupusMDSCmouse modelproteinuriaS100A9sex specific effectstype I interferon

Identifiers

PMID34220829
PMCPMC8248531
OpenAlexW3175709189

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.